EP2-漢康生技如何佈局全球抗癌版圖？How HanchorBio is Scaling Global Cancer Immunotherapy

【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作2025 年 6 月，漢康生技宣佈與復宏漢霖達成抗癌新藥 HCB101 的區域授權，總金額突破 2 億美元。這不僅是漢康的重要里程碑，更證明了臺灣生技研發實力已具備國際競爭力。本集節目特別邀請漢康生技商務開發長（CBO）叢越華博士，他擁有德國有機化學博士背景，並曾主導過數十億美元的國際授權案。叢博士將分享：科學與使命： 為什麼「先天免疫」是癌症治療的下一個關鍵？授權內幕： 為什麼復宏漢霖願意投資一家僅成立 5 年的 Startup？商戰策略： 專利保護（IP）如何從不同層度構築企業護城河？國際視野： 漢康生技如何從「0 到 1」跨入「1 到 100」的擴張期？無論您是專業投資人，還是關注生醫創新的朋友，這場科學與商務的精彩對談都不容錯過。In June 2025, HanchorBio achieved a major milestone by signing a $202 million regional licensing deal for HCB101 with Henlius. What makes a global pharmaceutical giant bet on a 5-year-old startup?In this episode, we sit down with Dr. Yuahua Cong, CBO of HanchorBio. With a PhD in Organic Chemistry from Germany and a track record of leading billion-dollar international deals, Dr. Chong shares insights into:The Science: Why innate immunity is the missing piece in the cancer immunotherapy puzzle.The Partnership: Why Henlius was chosen as the strategic partner for Greater China.IP Strategy: How HanchorBio builds a "moat" around its technology through multi-layered patent protection.Scaling Up: Why HanchorBio has already moved beyond the "Proof of Concept" phase into a global expansion stage.Join us for a deep dive into the intersection of groundbreaking science and high-stakes business negotiation.漢康生技官網：https://www.hanchorbio.com/漢康生技LinkedIn：https://reurl.cc/7b19y9本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。